Monoclonal antibody improves hidradenitis suppurativa by 55%

Monoclonal antibodies

UCB has revealed new data demonstrating a 55% improvement in adults with moderate to severe hidradenitis suppurativa (HS) treated with monoclonal antibody bimekizumab.

The data were presented at the 13th Conference of the European Hidradenitis Suppurativa Foundation (EHSF) in Lyon, France (7-9 February).

Emmanuel Caeymaex, Executive Vice President, Immunology Solutions, and Head of US, UCB, said: “Results presented re-affirm the high levels of sustained clinical response achieved with bimekizumab treatment, the positive impact on health-related quality of life as reported by patients, and the importance of timely treatment following diagnosis.”

The data show, at week 48, ~7 of 10 patients treated with bimekizumab achieved International Hidradenitis Suppurativa 4 (IHS4)-55, an IHS4 dichotomous outcome that measures treatment effect and signifies reduction in abscesses, nodules and draining tunnels.

Bimekizumab treatment demonstrated improvements in overall lesion count and lesion clearance, across abscesses, inflammatory nodules and draining tunnels over 48 weeks.

Patient-reported data showed that high levels of clinical responses observed with bimekizumab treatment translated into benefits in health-related quality of life.

“The achievement of IHS4-55 shows reduction in inflammatory nodules, abscesses and draining tunnels. This is a novel dichotomous version of the International Hidradenitis Suppurativa Severity Score System that allows for the inclusion and quantification of draining tunnels in a validated manner and reflects at least 55% improvement in the total score from baseline. With bimekizumab, the analyses showed that over 48 weeks, the majority of patients, ~7 out of 10, achieved IHS4-55,” said Professor Tzellos, Department of Dermatology, Nordland Hospital Trust, Bodø, Norway.

The company is keen to emphasise that the efficacy and safety of bimekizumab in HS have not been established and it is not approved for use in HS by any regulatory authority worldwide.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free